Reply to "Comment on "Fatal occurrence of acquired haemophilia A in a patient with pemphigus vulgaris".

08:00 EDT 11th October 2019 | BioPortfolio

Summary of "Reply to "Comment on "Fatal occurrence of acquired haemophilia A in a patient with pemphigus vulgaris"."

We have read with interest the comment by Dr Abdelmaksoud and Dr Vestita to our recently published article concerning a fatal occurrence of acquired haemophilia A (AHA) in a patient with pemphigus vulgaris (PV) . In this comment, the authors pointed out the possible presence of a smouldering haematologic malignancy (HM) in our patient, since both AHA and PV have been found to be associated with haematologic cancers, and in particular, lymphoproliferative disorders.


Journal Details

This article was published in the following journal.

Name: Clinical and experimental dermatology
ISSN: 1365-2230


DeepDyve research library

PubMed Articles [14574 Associated PubMed Articles listed on BioPortfolio]

The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.

Acquired haemophilia A (AHA) is a rare autoimmune bleeding disorder caused by the presence of autoantibodies against coagulation factor VIII (FVIII). The mortality rate remains high. International rec...

Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.

Epidemiological surveillance of haemophilia through linkage of medical records within a US state has not been conducted in 20 years.

The first reported case of acquired haemophilia A in which bleeding episodes were successfully treated via administration of a single-dose mixture of activated factor VIIa/X.

Comment on "Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis".

I read with interest a case report by Affleck et al. published in the journal of Clinical and Experimental Dermatology. The authors presented an 80-year-old patient on low-dose methotrexate (MXT) who...

FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management.

Clinical Trials [5334 Associated Clinical Trials listed on BioPortfolio]

Cardiovascular Disease (CVD) in Haemophilia

Life expectancy of hemophilia patients has improved considerably during the past decades and is approaching that of the general population. Hemophilia patients are therefore likely to be c...

Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.

This study aims to make an inventory of the condition and care of patients with haemophilia and carriers for haemophilia in Ivory Coast and to promote the use non substitutive strategies t...

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies

Life expectancy of haemophilia patients (specially severe) has dramatically increase in the last decades, which lead to the apparition of aging diseases such as cardiovascular disease, wit...

Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany

This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The primary aim is to observe the haemostatic efficacy of NovoSeven® treatment during routine practice in German clinic...

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

This study is conducted in the United States of America (USA). The aim of this study is to investigate the at-home-administration of bypassing agents for treatment of bleeding episodes in ...

Medical and Biotech [MESH] Definitions

Any adverse condition in a patient occurring as the result of treatment by a physician, surgeon, or other health professional, especially infections acquired by the patient during the course of treatment.

Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility.

Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.

A coronavirus first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SARS VIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.

The right of the patient or the patient's representative to make decisions with regard to the patient's dying.

Quick Search

DeepDyve research library

Searches Linking to this Article